DNA topoisomerase II in therapy-related acute promyelocytic leukemia. Mistry AR, Felix CA, Whitmarsh RJ, Mason A, Reiter A, Cassinat B, Parry A, Walz C, Wiemels JL, Segal MR, Adès L, Blair IA, Osheroff N, Peniket AJ, Lafage-Pochitaloff M, Cross NC, Chomienne C, Solomon E, Fenaux P, Grimwade D (2005) N Engl J Med 352: 1529-38 Phase I clinical and pharmacokinetic study of high-dose mitoxantrone combined with carboplatin, cyclophosphamide, and autologous bone marrow rescue: high response rate for refractory ovarian carcinoma. Stiff PJ, McKenzie RS, Alberts DS, Sosman JA, Dolan JR, Rad N, McCloskey T (1994) J Clin Oncol 12: 176-83 High-dose chemotherapy combined with escalating doses of cyclosporin A and an autologous bone marrow transplant for the treatment of drug-resistant solid tumors: a phase I clinical trial. Stiff PJ, Bayer R, Tan S, Camarda M, Sosman J, Peace D, Kinch L, Rad N, Loutfi S (1995) Clin Cancer Res 1: 1495-502 Etoposide: four decades of development of a topoisomerase II inhibitor. Hande KR (1998) Eur J Cancer 34: 1514-21 A phase II trial of high-dose mitoxantrone, carboplatin, and cyclophosphamide with autologous bone marrow rescue for recurrent epithelial ovarian carcinoma: analysis of risk factors for clinical outcome. Stiff P, Bayer R, Camarda M, Tan S, Dolan J, Potkul R, Loutfi S, Kinch L, Sosman J, Peace D (1995) Gynecol Oncol 57: 278-85 Quality of life with advanced metastatic prostate cancer. Resnick MJ, Penson DF (2012) Urol Clin North Am 39: 505-15
Hints: (1) double-click or double-tap to navigate to a node. (2) Grab a node and move it to arrange the graph.